Description
PP49 Ravulizumab* (ALXN1210) vs eculizumab in complement inhibitor-naive adult patients with PNH
Article: PP49 Ravulizumab* (ALXN1210) vs eculizumab in complement inhibitor-naive adult patients with PNH
€3.03
Related products
-
Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma
€3.03 Add to cart -
Article: Highlights in breast cancer
€3.03 Add to cart -
Article: Highlights in digestive oncology
€3.03 Add to cart -
1 year access Online Belgian Journal of Hematology (BJH)
€71.94 Add to cart
Reviews
There are no reviews yet.